Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue and EBITDA growth in its Interims to September.</li>
<li>Revenue improved from £1.1m to £2.2m with EBITDA up from £0.1m to £0.7m.</li>
<li>The cash balances of £2.2m is allowing an interim dividend of 1.2p per share to be paid to shareholders on the register on 12 December. </li>
</ul>


The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue and EBITDA growth in its Interims to September.
Revenue improved from £1.1m to £2.2m with EBITDA up from £0.1m to £0.7m.
The cash balances of £2.2m is allowing an interim dividend of 1.2p per share to be paid to shareholders on the register on 12 December. 


Trellus Health Plc - Hybridan Small Cap Feast: 24 November 2025

<ul>
<li>The exploration and development Company with projects in Greenland and Finland has entered into a Binding Head of Terms with USFM Corporation to fund $30m to earn 51% of the DiskoNuussuaq project in West Greenland.</li>
<li>80 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive agreements.</li>
<li>The new funds are to be directed towards drilling rather than reprocessing data with a minimum of $10m to be spent within 10 months of the signing. </li>
</ul>


The exploration and development Company with projects in Greenland and Finland has entered into a Binding Head of Terms with USFM Corporation to fund $30m to earn 51% of the DiskoNuussuaq project in West Greenland.
80 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive agreements.
The new funds are to be directed towards drilling rather than reprocessing data with a minimum of $10m to be spent within 10 months of the signing. 


Hybridan Small Cap Feast: 03 November 2025

<ul>
<li>Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.</li>
<li>The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.</li>
<li>As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. </li>
</ul>


Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.
The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.
As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. 


Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

Beeks Financial Cloud Group / Equity Bottom-Up

<ul>
<li>The biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.</li>
<li>The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an Automated Insulin Delivery (AID) system, ahead of a planned Investigational New Drug (IND) submission.</li>
<li>Arecor reports they are on track to commence Phase 2 study in mid-2026, subject to further funding.</li>
</ul>


The biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces that it has concluded a positive Type C meeting with the US Food and Drug Administration (FDA) for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs.
The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an Automated Insulin Delivery (AID) system, ahead of a planned Investigational New Drug (IND) submission.
Arecor reports they are on track to commence Phase 2 study in mid-2026, subject to further funding.


<ul>
<li>1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.</li>
<li>There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.</li>
<li>The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. </li>
</ul>


1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.
There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.
The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. 


United Kingdom

Fusion Antibodies Ltd operates as a bio-technology company. The Company develops antibodies for therapeutic drug and diagnostic applications. Fusion Antibodies also renders antibody class switching, stable cell line development, mammalian transient and bacterial protein expression, custom monoclonal antibody production, and sequencing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Trellus Health Plc - Hybridan Small Cap Feast: 24 November 2025

The mid-market, challenger professional services platform and owner of the Dow Schofield Watts and the DR Solicitors brands reported strong revenue...

Hybridan

Hybridan Small Cap Feast: 03 November 2025

0 Mile as the operator and will receive a management fee of 12.5% of the total expenditure as well as a £0.5m payment upon signing definitive...

Hybridan

Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and...

Hybridan

Hybridan Small Cap Feast: 04/09/2025

The purpose of the meeting was to discuss the design of a proposed Phase 2 clinical study for AT278 delivered by continuous infusion via an...

Hybridan

Hybridan Small Cap Feast: 07/05/2025

1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)